title: Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010.
abstract: The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is a nationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA; n = 759), vancomycin-resistant Enterococcus faecium (VRE; n = 191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n = 602), ESBL-producing Klebsiella pneumoniae (n = 736), and Acinetobacter baumannii (n = 726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC(90) values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were <5% for MRSA, VRE, and ESBL-producing E. coli. For routine susceptibility testing of ESBL-producing K. pneumoniae and A. baumannii against tigecycline, the broth microdilution method should be used because of the poor correlation of results between these two methods.
authors.affiliation: Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University Medical College, Kaohsiung, Taiwan.
authors.forename: Jien-Wei
authors.initials: JW
authors.lastname: Liu
authors.forename: Wen-Chien
authors.initials: WC
authors.lastname: Ko
authors.forename: Cheng-Hua
authors.initials: CH
authors.lastname: Huang
authors.forename: Chun-Hsing
authors.initials: CH
authors.lastname: Liao
authors.forename: Chin-Te
authors.initials: CT
authors.lastname: Lu
authors.forename: Yin-Ching
authors.initials: YC
authors.lastname: Chuang
authors.forename: Shih-Ming
authors.initials: SM
authors.lastname: Tsao
authors.forename: Yao-Shen
authors.initials: YS
authors.lastname: Chen
authors.forename: Yung-Ching
authors.initials: YC
authors.lastname: Liu
authors.forename: Wei-Yu
authors.initials: WY
authors.lastname: Chen
authors.forename: Tsrang-Neng
authors.initials: TN
authors.lastname: Jang
authors.forename: Hsiu-Chen
authors.initials: HC
authors.lastname: Lin
authors.forename: Chih-Ming
authors.initials: CM
authors.lastname: Chen
authors.forename: Zhi-Yuan
authors.initials: ZY
authors.lastname: Shi
authors.forename: Sung-Ching
authors.initials: SC
authors.lastname: Pan
authors.forename: Jia-Ling
authors.initials: JL
authors.lastname: Yang
authors.forename: Hsiang-Chi
authors.initials: HC
authors.lastname: Kung
authors.forename: Chun-Eng
authors.initials: CE
authors.lastname: Liu
authors.forename: Yu-Jen
authors.initials: YJ
authors.lastname: Cheng
authors.forename: Yen-Hsu
authors.initials: YH
authors.lastname: Chen
authors.forename: Po-Liang
authors.initials: PL
authors.lastname: Lu
authors.forename: Wu
authors.initials: W
authors.lastname: Sun
authors.forename: Lih-Shinn
authors.initials: LS
authors.lastname: Wang
authors.forename: Kwok-Woon
authors.initials: KW
authors.lastname: Yu
authors.forename: Ping-Cherng
authors.initials: PC
authors.lastname: Chiang
authors.forename: Ming-Hsun
authors.initials: MH
authors.lastname: Lee
authors.forename: Chun-Ming
authors.initials: CM
authors.lastname: Lee
authors.forename: Gwo-Jong
authors.initials: GJ
authors.lastname: Hsu
authors.forename: Po-Ren
authors.initials: PR
authors.lastname: Hsueh
mesh_terms: D040981:Acinetobacter baumannii / Q000187:drug effects / Q000254:growth & development; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D016984:Enterococcus faecium / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D006801:Humans; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D008137:Longitudinal Studies; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013624:Taiwan; D000078304:Tigecycline; D014640:Vancomycin / Q000494:pharmacology; D001618:beta-Lactamases / Q000096:biosynthesis
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D014640:Vancomycin; D000078304:Tigecycline; D001618:beta-Lactamases; D008911:Minocycline